Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
2023; Lippincott Williams & Wilkins; Volume: 41; Issue: 23 Linguagem: Inglês
10.1200/jco.22.02567
ISSN1527-7755
AutoresMartin Kaiser, Andrew Hall, Katrina Walker, Amy L. Sherborne, Ruth M. de Tute, Nicola Newnham, Sadie Roberts, Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Roger G. Owen, Mark T. Drayson, Sarah Brown, Matthew Jenner,
Tópico(s)Peptidase Inhibition and Analysis
ResumoThe multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) before and after autologous stem-cell transplant (ASCT) in newly diagnosed patients with molecularly defined ultra-high-risk (UHiR) multiple myeloma (NDMM) or plasma cell leukemia (PCL). To provide clinical context, progression-free survival (PFS) and overall survival (OS) were referenced to contemporaneous outcomes seen in patients with UHiR NDMM treated in the recent Myeloma XI (MyeXI) trial.
Referência(s)